高放射性:锆-89是一种常用于正电子发射断层扫描(PET)的放射性同位素。 高水溶性和生物相容性:PEG修饰提高了化合物的水溶性和在体内的生物相容性。 综上所述,MTzL/BCNL、3,6-二甲酯基-1,2,4,5-四嗪以及[Zr-89]Zr-DFO-PEG(5)-Tz([Zr-89]Zr-DFO-PEG(5)-Tetrazine)都是具有特定结构和性质的化合物,...
组成:该化合物由放射性同位素Zr-89标记的锆离子(Zr)、去铁胺(DFO)、五聚乙二醇(PEG5)和四嗪(Tetrazine/Tz)组成。 特性: Zr-89:一种放射性同位素,具有较长的半衰期和适中的能量释放,常用于PET(正电子发射断层扫描)成像。 DFO:一种能够与金属离子形成稳定络合物的配体,常用于放射性同位素的标记和传递。 PEG5:...
Here, we demonstrate that89Zr-DFO*-immuno-PET can be used to visualize and quantify brain uptake of mAbs and contribute to the evaluation of biological therapeutics for brain diseases.doi:10.1007/s00259-023-06109-3N. Stergiougrid.12380.380000 0004 1754 9227Radiology & Nuclear MedicineAmsterdam UMC...
目的:设计合成靶向PD-1新型分子探针89Zr-DFO-G4C2,研究该探针在荷瘤小鼠的体内生物分布特性及micro PET/CT显像效果,探讨89Zr-DFO-G4C2 PET/CT显像用于PD-1抑制剂免疫治疗监测的潜在临床应用价值.方法:1,DFO偶联抗PD-1单克隆抗体G4C2,合成DFO-G4C2,BCA试剂盒测定DFO-G4C2蛋白浓度,SPR技术鉴定DFO-G4...
Lesion detection by [ 89 Zr]Zr-DFO-girentuximab and [ 18 F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinomaLesion detection by [ 89 Zr]Zr-DFO-girentuximab and [ 18 F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinomaCAIXClear...
百度爱采购为您找到0条最新的89zr-dfo-daratumumab 镐产品的详细参数、实时报价、行情走势、优质商品批发/供应信息,您还可以免费查询、发布询价信息等。
Girentuximab是一种靶向碳酸酐酶IX (CAIX)的单克隆抗体,碳酸酐酶IX在透明细胞肾癌(ccRCC)中高度表达。既往研究表明CAIX显像是可行的,而其他研究表明89Zr-DFO-girentuximab是安全的,可以在给药后4 - 7天显像ccRCC。——出国看病 因此,Shuch等开展了3期ZIRCON研究,评估89Zr-DFO-girentuximab PET/CT检测ccRCC的性能...
89Zr-DFO-J591 was produced in high radiochemical yield (>77%) and purity (>99%), with a specific activity of 181.7 ± 1.1 MBq/mg (4.91 ± 0.03 mCi/mg). In vitro assays demonstrated that 89Zr-DFO-J591 had an initial immunoreactive fraction of 0.95 ± 0.03 and remained active for ...
[89Zr]Zr-DFO-denosumab immuno-PET validation in the tumor microenvironment of human ME-180 xenograftsdoi:10.1016/S0969-8051(21)00270-5Jonatan DewulfChristel VangestelTim Van den WyngaertFilipe ElvasElsevier BVNuclear Medicine and Biology
This result is in agreement with the low uptake of Zr-89-DFO-cetuximab in FCR cells. Tumor uptake of Zr-89-DFO-cetuximab in FCR was significantly lower than FCS tumors (p = 0.0340). Conclusions: In this work, the authors showed that Zr-89-DFO-cetuximab is suitable for identification of...